Cognition Therapeutics INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Cognition Therapeutics, a clinical-stage biopharmaceutical company, reported its 2025 annual results, highlighting progress in its zervimesine clinical programs for Alzheimer's and Lewy body dementia, while facing continued net losses and capital needs.
NASDAQ
10-K: Cognition Therapeutics Reports 2024 Results, Prioritizes Alzheimer's and Lewy Body Dementia Programs
Cognition Therapeutics focuses on Alzheimer's and Lewy Body Dementia programs after reporting 2024 results and discontinuing the MAGNIFY study in dry AMD.
NASDAQ
Cognition Therapeutics, a clinical-stage biopharmaceutical company, details its financial performance for 2023 and outlines progress in its clinical programs targeting age-related degenerative diseases.